Welcome to our dedicated page for Serina Therapeutics news (Ticker: ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Serina Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Serina Therapeutics's position in the market.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company focused on its POZ Platform™ drug optimization technology, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Steve Ledger will deliver a presentation on September 8, 2025, at 9:30 a.m. ET in New York.
The presentation will be available via live webcast for registered attendees, with an on-demand replay accessible for 90 days after the event.
Serina Therapeutics (NYSE American: SER) received positive FDA feedback supporting the advancement of SER-252, their POZ-enabled apomorphine treatment for advanced Parkinson's disease, through a 505(b)(2) NDA pathway. The company plans to initiate a registrational clinical study program with a comprehensive development strategy.
Key upcoming milestones include U.S. IND submission in Q4 2025, patient dosing in Australia in Q4 2025, and U.S. enrollment beginning in Q1 2026. The registrational study, SER-252-1b, is designed as a randomized, double-blind, placebo-controlled Phase 1b trial, evaluating safety, tolerability, and pharmacokinetics in Parkinson's disease patients with motor fluctuations.
Serina Therapeutics (NYSE American: SER) reported its Q2 2025 financial results and business updates. The company recorded a net loss of $6.4 million ($0.66 per share) compared to net income of $5.2 million in Q2 2024. Revenue increased to $130,000 from $51,000 year-over-year.
Key developments include the advancement of SER-270, a once-weekly injectable therapy for tardive dyskinesia, the appointment of Dr. Stephen Brannan to the Board, and securing $5 million in funding for SER-252 development. The company raised $1.2 million through ATM offerings and ended Q2 with $6.0 million in cash, expected to fund operations into Q4 2025.
Operating expenses increased to $5.7 million, with R&D expenses doubling to $3.2 million year-over-year. The company's lead candidate SER-252 for advanced Parkinson's disease is scheduled to enter clinical trials in Q4 2025.
Serina Therapeutics (NYSE:SER) announced the advancement of SER-270 (POZ-VMAT2i), a novel once-weekly injectable VMAT2 inhibitor for treating tardive dyskinesia (TD). The drug leverages Serina's proprietary POZ Platform™ technology to provide a long-acting alternative to daily oral medications.
The U.S. TD market, which exceeded $3.7 billion in sales in 2024, is projected to reach $5.4 billion by 2030. Currently, fewer than 30% of U.S. TD patients are diagnosed, with less than half receiving treatment. The company also plans to explore the drug's potential for treating chorea associated with Huntington's disease.
POZ-VMAT2i specifically targets underserved patients who struggle with daily medication adherence, institutionalized patients, and those with dysphagia, offering a potentially transformative solution in the VMAT2 inhibitor market.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company focused on its proprietary POZ Platform™ drug optimization technology, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. CEO Steve Ledger will engage in a fireside chat on Tuesday, July 29, 2025, at 2:00 p.m. ET during the two-day conference scheduled for July 29-30, 2025.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to a new non-executive employee. The inducement grant consists of options to purchase 12,500 shares of common stock, with an exercise price matching the closing price on June 18, 2025.
The Option Grant, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, aims to align employee interests with stockholders and was made in compliance with NYSE American's Company Guide Section 711(a).
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company, has announced its 2025 Annual Stockholders Meeting will be held on November 7, 2025. The specific time and location will be detailed in the company's definitive proxy statement to be filed with the SEC.
Due to the meeting date change of more than 30 days from the 2024 annual meeting anniversary, stockholder proposals under Rule 14a-8 must be submitted by 5:00 p.m. (Central Time) on August 15, 2025. For stockholder proposals and director nominations under the company's bylaws, submissions must be received between July 10, 2025, and August 9, 2025 at the company's Huntsville, Alabama headquarters.
Serina Therapeutics (NYSE American: SER) announced its CEO Steve Ledger will present at a FORCE Family Office investor webinar on June 26, 2025, at 12:00 p.m. ET. The presentation, titled "New Drug Optimization Platform to Transform Parkinson's Care," will focus on the company's drug candidate SER-252, a polymer conjugate of apomorphine designed to provide continuous dopaminergic stimulation for Parkinson's disease treatment.
The webinar will highlight the company's POZ Platform™ technology and its potential to improve safety, duration, and tolerability of Parkinson's treatments. The event will include a Q&A session hosted by FORCE Family Office CEO Steve Saltzstein.
FAQ
What is the current stock price of Serina Therapeutics (ser)?
What is the market cap of Serina Therapeutics (ser)?
